Accelerate with Lotus® technology.

services and platforms to speed innovation to market

WELCOME TO BOSTON MOUNTAIN BIOTECH

At Boston Mountain Biotech, we don’t design new drugs, we help manufacture drugs more efficiently.

The Lotus platform addresses the need of the pharmaceutical industry to reduce the cost of manufacturing protein pharmaceuticals. BMB has targeted the greatest area of process loss, inefficient downstream separations, which is 70% of all manufacturing costs through the development of the Lotus platform. The Lotus platform comprises genetically modified host cells that improve the efficiency of downstream chromatography via improving column capacity by at least 35%. This improvement increases the throughput of material through the chromatography unit, saving time, while decreasing resin and buffer usage, which reduces the highest operating and material costs in downstream purification. The Lotus platform is compatible with existing validated manufacturing equipment and processes, and improves drug purification efficiency without negatively affecting upstream expression efficiencies.

MORE ABOUT US

NEWS

BMB Intern Honored by Millipore Sigma

Congratulations to Dr. Rudra Palash Mukherjee, a former graduate student of our collaborator Dr. Beitle and a student intern for Boston Mountain Biotech. Rudra was selected as one of the four finalists for the Millipore Sigma's 2016 Life Science Award in Bioseparations for his innovative research towards the development of a recombinant peptide production and purification platform. (more…)

BMB Awarded an NSF Phase I STTR

The National Science Foundation (NSF) has awarded Boston Mountain Biotech a Phase I STTR (small business technology transfer) commercialization grant for the "Harnessing CRISPR-mediated silencing for the one-step optimization of protein production strains".

Genetic Engineering of Cell Lines for Improved Performance

Author Angela De Palma, Ph.D. of GEN News recently highlighted the growing practice of using genetic engineering to improve pharmaceutical manufacturing productivity. Her article, in particular, focuses on the genetic engineering of Chinese Hamster Ovary (CHO) cells for the production of recombinant proteins. (more…)

The Lotus® platform links downstream contaminating host cell proteins (HCPs) to potential upstream cell line modifications, causing a boost in chromatographic efficiency. This allows manufacturers to shorten their development time while having a minimal impact on equipment and FDA approval.

LEARN MORE